NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY
This announcement is for information purposes only and does not constitute an offer to sell or the solicitation of an offer to buy securities. This announcement does not contain all of the information that is material to an investor and is not required under the indenture dated May 3, 2023, entered into for the issuance of the 6½% senior secured notes due 2029.
Milan, 21st of March – The Board of Directors of Kevlar S.p.A. has today approved the following key preliminary results for the year ended December 31, 2023 (“FY 2023”).
HIGHLIGHTS
Revenue increased by €287.6 million, or 25%, to €1.429 million for the Full Year 2023, from €1.142(1) million for the Full Year 2022. This strong performance has been mainly driven by the increase in the sale of plasma and Plasma-Derived products.
Reported EBITDA increased by €85.1 million, or 88%, to €181.8 million for the Full Year 2023, from €96.6(1) million for the Full Year 2022.
Management Adjusted EBITDA increased by €45.5 million, or 24%, to €232.8 million for the Full Year 2023, from €187.3(1) million for the FY 2023.
The individual and consolidated financial statements for the year ended 31 December 2023 will be submitted to the Annual General Meeting of Stockholders by April 12th, 2024.
About Kedrion
Kedrion is a leading global biopharmaceutical company specializing in the collection of plasma and in the development, production, and distribution of plasma-derived therapeutic products for use in treating and preventing rare and debilitating conditions like Coagulation and Neurological Disorders, and Primary and Secondary Immunodeficiencies. Headquartered in Italy and with a commercial presence in over 100 countries, as of December 31, 2023, Kedrion owned and operated 68 plasma collection centers and seven manufacturing plants worldwide.
(1) Based on pro forma figures 2022
